|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.48 USD | -0.38% |
|
-0.47% | -28.95% |
| 07-30 | Daxor Launches Blood Testing Lab in Eastern Kansis | MT |
| 07-30 | Daxor Corporation Initiates Outpatient Blood Volume Analysis Program in Kansas | CI |
| Market Cap | 61.3M 53.07M 49.48M 45.53M 85.9M 5.83B 86.89M 581M 228M 2.92B 230M 225M 9.67B | P/E 2026 * |
-50.1x | P/E 2027 * | -351x |
|---|---|---|---|---|---|
| Enterprise Value | 61.3M 53.07M 49.48M 45.53M 85.9M 5.83B 86.89M 581M 228M 2.92B 230M 225M 9.67B | EV / Sales 2026 * |
5.15x | EV / Sales 2027 * | 2.95x |
| Free-Float |
46.74% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Daxor Corporation
| 1 week | -0.47% | ||
| Current month | -0.19% | ||
| 1 month | +0.96% | ||
| 3 months | -3.44% | ||
| 6 months | -14.52% | ||
| Current year | -28.95% |
| 1 week | 10.11 | 11 | |
| 1 month | 10.05 | 11.97 | |
| 3 years | 6.55 | 14.76 | |
| 5 years | 6.55 | 14.76 | |
| 10 years | 3.4 | 24.08 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 2012-12-31 | |
Robert Michel
DFI | Director of Finance/CFO | 69 | 2018-09-27 |
John Jefferies
CTO | Chief Tech/Sci/R&D Officer | - | 2024-06-04 |
| Director | Title | Age | Since |
|---|---|---|---|
James Lombard
BRD | Director/Board Member | 91 | 1988-12-31 |
| Chairman | 56 | 2017-02-13 | |
Edward Feuer
BRD | Director/Board Member | 70 | 2016-06-21 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.38% | -0.47% | +5.12% | +9.36% | 61.3M | ||
| +4.08% | +5.62% | +24.15% | +112.92% | 14.64B | ||
| +4.55% | +9.47% | +59.42% | +150.99% | 12.23B | ||
| -0.20% | +4.45% | -3.90% | +31.14% | 9.37B | ||
| +4.17% | +6.87% | +37.61% | +132.77% | 7.54B | ||
| -0.80% | -0.31% | -16.99% | -17.29% | 7.45B | ||
| -0.23% | +0.35% | +14.49% | +42.70% | 6.38B | ||
| -0.13% | -0.52% | +9.26% | +23.11% | 4.76B | ||
| -0.65% | -2.64% | +8.53% | +6.37% | 4.05B | ||
| -0.65% | +4.70% | - | - | 3.83B | ||
| Average | +1.13% | +1.95% | +15.30% | +54.67% | 7.81B | |
| Weighted average by Cap. | +1.88% | +2.29% | +20.63% | +76.29% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 11.9M 10.3M 9.6M 8.84M 16.67M 1.13B 16.87M 113M 44.25M 566M 44.69M 43.71M 1.88B | 20.8M 18.01M 16.79M 15.45M 29.14M 1.98B 29.48M 197M 77.34M 989M 78.11M 76.4M 3.28B |
| Net income | -1.2M -1.04M -969K -891K -1.68M -114M -1.7M -11.38M -4.46M -57.08M -4.51M -4.41M -189M | -200K -173K -161K -149K -280K -19.02M -283K -1.9M -744K -9.51M -751K -735K -31.54M |
| Net Debt | - | - |
Employees
-
Sector
Closed End Funds
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-05 | US$10.48 | -0.38% | 314 |
| 26-08-04 | US$10.52 | -3.04% | 3,119 |
| 26-08-03 | US$10.85 | +3.33% | 689 |
| 26-07-31 | US$10.50 | - | 870 |
| 26-07-30 | US$0.000000 | -100.00% | 115 |
Sell
Buy

Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.52USD
Average target price
22.50USD
Spread / Average Target
+113.88%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- DXR Stock
- DXR Stock
Select your edition
All financial news and data tailored to specific country editions

















